These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 18507107

  • 1. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.
    Takaki Y, Kaminou T, Shabana M, Ihaya T, Otsubo K, Ogawa T.
    Hepatogastroenterology; 2008; 55(81):202-6. PubMed ID: 18507107
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
    Maeda S, Shibata J, Fujiyama S, Tanaka M, Noumaru S, Sato K, Tomita K.
    Hepatogastroenterology; 2003; 50(51):809-13. PubMed ID: 12828090
    [Abstract] [Full Text] [Related]

  • 3. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
    Koizumi Y, Hirooka M, Uehara T, Kisaka Y, Uesugi K, Kumagi T, Abe M, Matsuura B, Hiasa Y, Onji M.
    Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
    [Abstract] [Full Text] [Related]

  • 4. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma.
    Kawaoka T, Aikata H, Katamura Y, Takaki S, Waki K, Hiramatsu A, Takahashi S, Hieda M, Kakizawa H, Chayama K.
    J Vasc Interv Radiol; 2010 Aug; 21(8):1219-25. PubMed ID: 20619676
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy and toxicity of transcatheter arterial chemoembolization with Cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma].
    Uyama N, Hatano E, Maetani Y, Isoda H, Shibata T, Taura K, Oe S, Naito M, Yasuchika K, Fujii H, Ikai I, Uemoto S.
    Gan To Kagaku Ryoho; 2008 May; 35(5):775-80. PubMed ID: 18487912
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of emulsion containing Gd-DTPA and lipiodol in hepatic transcatheter arterial embolization.
    Shiono T, Yoshikawa K, Hisamatsu K, Takenaka E.
    Radiat Med; 1993 May; 11(5):187-90. PubMed ID: 8290693
    [Abstract] [Full Text] [Related]

  • 7. [Anticancer and side effect of arterial subsegmental chemoembolization using cisplatinum/pirarubicin lipiodol suspension (CTLS) for hepatocellular carcinoma].
    Inoue H, Miyazono N, Kanetsuki I, Hori A, Tanaka D, Fukukura Y, Matsumoto Y, Nishida H, Ueno K, Nakajo M.
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1973-6. PubMed ID: 7692822
    [Abstract] [Full Text] [Related]

  • 8. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
    Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Yumoto Y, Mori T, Oda T.
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma.
    Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M.
    Hepatology; 1997 Nov; 26(5):1156-61. PubMed ID: 9362356
    [Abstract] [Full Text] [Related]

  • 10. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.
    Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G.
    J Vasc Interv Radiol; 2001 Jul; 12(7):847-54. PubMed ID: 11435541
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study.
    Baur M, Walter R, Gebauer A, Tscholakoff D, Lochs H, Mühlbacher F, Turetschek K, Binder R, Hudec M, Gangl A, Ferenci P, Dittrich C.
    Int J Oncol; 2003 Sep; 23(3):811-9. PubMed ID: 12888922
    [Abstract] [Full Text] [Related]

  • 13. [Chemoembolization therapy with cisplatin.lipiodol (CDDP.lipiodol) in primary liver cancer--with special reference to hepatocellular carcinoma].
    Yodono H, Tarusawa K, Kanehira J, Fukuda E, Ikami I, Sakaki T, Kamata K, Sasaki D, Sasaki M.
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3476-82. PubMed ID: 3024580
    [Abstract] [Full Text] [Related]

  • 14. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
    Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.
    Jpn J Clin Oncol; 2012 Mar; 42(3):175-82. PubMed ID: 22210921
    [Abstract] [Full Text] [Related]

  • 15. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.
    Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J.
    Hepatology; 2002 May; 35(5):1164-71. PubMed ID: 11981766
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [Abstract] [Full Text] [Related]

  • 17. Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases.
    Kenji J, Hyodo I, Tanimizu M, Tanada M, Nishikawa Y, Hosokawa Y, Mandai K, Moriwaki S.
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-71-S6-80. PubMed ID: 9151920
    [Abstract] [Full Text] [Related]

  • 18. [Studies on drug release from anti-cancer drug suspended Lipiodol].
    Isshiki K, Kishimoto W, Nonami T, Kato H, Haba T, Nakao A, Harada A, Takagi H, Kato M, Mizoguchi M.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3019-23. PubMed ID: 2551242
    [Abstract] [Full Text] [Related]

  • 19. Ionic versus nonionic contrast media solvents used with an epirubicin-based agent for transarterial chemoembolization of hepatocellular carcinoma.
    Tzeng WS, Wu RH, Chang SC, Chou CK, Lin CY, Chen JJ, Yang SC, Lin CH.
    J Vasc Interv Radiol; 2008 Mar; 19(3):342-50. PubMed ID: 18295692
    [Abstract] [Full Text] [Related]

  • 20. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
    Yodono H, Matsuo K, Shinohara A.
    Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.